Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

10.58
-0.1900-1.76%
Post-market: 10.580.00000.00%19:30 EDT
Volume:3.72M
Turnover:38.27M
Market Cap:900.43M
PE:-2.77
High:10.80
Open:10.75
Low:10.00
Close:10.77
52wk High:23.29
52wk Low:8.80
Shares:85.11M
Float Shares:55.47M
Volume Ratio:1.97
T/O Rate:6.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8139
EPS(LYR):-3.5300
ROE:-67.47%
ROA:-32.44%
PB:2.10
PE(LYR):-3.00

Loading ...

Dec 18, 2024

Major Issues Report

Form 8-K - Current report
Nov 07, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 07, 2024

Major Issues Report

Form 8-K - Current report
Oct 08, 2024

Beneficial Ownership Change

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Sep 11, 2024

Major Issues Report

Form 8-K - Current report
Aug 07, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 07, 2024

Major Issues Report

Form 8-K - Current report
Jun 10, 2024

Major Issues Report

Form 8-K - Current report
Jun 06, 2024

Major Issues Report

Form 8-K - Current report
May 08, 2024

Correspondence

Form CORRESP - Correspondence
May 07, 2024

Major Issues Report

Form 8-K - Current report
May 07, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 07, 2024

[Rev.]Annual Report

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
Mar 11, 2024

Major Issues Report

Form 8-K - Current report
Mar 05, 2024

Beneficial Ownership Change

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
Feb 29, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 29, 2024

Major Issues Report

Form 8-K - Current report
Feb 26, 2024

Major Issues Report

Form 8-K - Current report
Feb 16, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Feb 15, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]